Floatz logo

Rosuvastatin

Cardiovascular Disorder

Nanjing First Hospital, Nanjing Medical UniversitySmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Cardiovascular Disorder cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Lipitor
Duke University
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB
RAMIFENTANYL
Helse Fonna
Phase 4BBB

View all 50 →

Same molecule, other indications

Rosuvastatin is also rated in:

inherited lipid metabolism disorderDormant
A
Indicative ·
81 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative ·
77 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →